Business
BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis
VANCOUVER, BC / ACCESS Newswire / February 17, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that the European ...
About this update from Bionxt Solutions Inc
[{"type":"text","content":"VANCOUVER, BC / ACCESS Newswire / February 17, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that the European Patent Office (EPO) has issued a Decision to Grant European Patent No. 4539857 covering the Company's proprietary sublingual cladribine oral thin film (ODF) drug delivery technology.","length":456,"tagName":"p"},{"type":"text","content":"The grant will take effect upon publication of the mention of grant in the European Patent Bulletin on March 11, 2026 (Bulletin 26/11). Upon assignment in designated jurisdictions, the patent will provide protection in up to 39 European Patent Convention (EPC) Contracting States. The patent term extends through at least June 14, 2043, subject to applicable validation requirements, renewal fees, and national procedures.","length":422,"tagName":"p"},{"type":"text","content":"The European Decision to Grant follows the Company's previously announced "Intention to Grant" communication from the EPO and represents a significant advancement in securing enforceable intellectual property rights in one of the world's largest pharmaceutical regions.","length":287,"tagName":"p"},{"type":"text","content":"A Defining Milestone in BioNxt's European Commercial Strategy","length":65,"tagName":"p"},{"type":"text","content":""The European patent decision represents an important milestone for BioNxt," said Hugh Rogers, CEO of BioNxt. "Europe is a core component of our long-term commercialization strategy. Securing patent protection in this region strengthens our global intellectual property position and supports our ongoing licensing and partnership discussions."","length":363,"tagName":"p"},{"type":"text","content":"Rogers continued, "This development builds on our recent Eurasian patent grant and aligns with the progress of our cladribine program as we prepare for planned human bioequivalence studies. With intellectual property protection advancing across multiple jurisdictions, BioNxt continues to establish a globally defensible platform around our sublingual cladribine technology."","length":385,"tagName":"p"},{"type":"text","content":"Protecting a Patient-Focused, Needle-Free Drug Delivery P...